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I read with great interest the recent article by Hameed et al in a recent issue of your 
journal.1 The article is very interesting. Interestingly, the past few years have seen the 
emergence of capecitabine as a highly potent first-line chemotherapeutic agent against 
advanced systemic carcinomas other than colorectal carcinoma.
For instance, capecitabine has recently been used successfully as a first-line 
monotherapeutic agent for HER-2-negative metastatic breast cancer.2 Cotherapy 
with agents such as sorafenib and paclitaxel for HER-2-negative metastatic breast 
cancer has also been recently used first-line, and significantly improves progression-
free survival, in addition to being very safe.3,4 Similarly, in patients with advanced 
gastric carcinoma, capecitabine has been used successfully as first-line therapy 
in combination with agents such as cisplatin.5 The XELOX regimen comprising 
capecitabine in conjunction with oxaliplatin is another recent highly effective 
alternative for gastric carcinoma.6 The modified XELIRI regimen compromising 
capecitabine and irinotecan is a further option for advanced and unresectable 
gastric carcinoma.7
Capecitabine also improves the short-term response in patients with esophageal 
carcinoma when used as an adjunct to radiotherapy.8 Further, a response rate of 26.7% 
has recently been reported in patients with advanced biliary carcinoma treated with 
a combination of capecitabine and fixed dose rate gemcitabine therapy.9 Similarly, 
capecitabine has recently been shown to be highly effective in the management of 
patients with recalcitrant castrate-resistant prostate cancer when used in combina-
tion with prednisone, thalidomide, and cyclophosphamide.10 Capecitabine in com-
bination with cisplatin has also been used as first-line therapy for nasopharyngeal 
carcinoma, with a response rate as high as 53.8%.11
The above examples clearly illustrate the efficacy of capecitabine as a potent 
agent against multiple carcinomas, ranging from breast carcinoma to nasopharyngeal 
carcinoma. Further studies are needed to identify further potential applications of 
capecitabine in other advanced carcinomas.
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